Junho Chung
Junho Chung
Emerging technologies for minimal residual disease detection in hematologic malignancies [0.03%]
血液系统恶性肿瘤中最小残余病灶检测的新兴技术
Daniel J Groso,David G Coffey
Daniel J Groso
Minimal residual disease (MRD) detection plays a critical role in determining prognosis, guiding therapy, and monitoring relapse in hematologic malignancies. Current gold-standard assays rely on flow cytometry, polymerase chain reaction (PC...
MRD in multiple myeloma: From an early endpoint for accelerated approval to MRD driven treatment and clinical management [0.03%]
多发性骨髓瘤中的微小残留病灶：从加速批准的有效终点到以微小残留病灶为导向的治疗和临床管理
Ola Landgren,Rafat Abonour,Dickran Kazandjian
Ola Landgren
The integration of minimal residual disease (MRD) assessment into multiple myeloma research and care has transformed the therapeutic and regulatory landscape. Building upon decades of progress in genomics, immunophenotyping, and high-sensit...
Repositioning neutrophils in cancer immunotherapy: From innate defenders to antibody-driven effectors [0.03%]
从固有免疫防御者到抗体介导的效应细胞：癌症免疫治疗中中性粒细胞的作用重新定位
Jisun Lee,Bomi Kim,Sang Taek Jung
Jisun Lee
Neutrophils, the most abundant innate immune cell population in human circulation, serve as frontline defenders through canonical mechanisms including degranulation, generation of reactive oxygen species (ROS), and neutrophil extracellular ...
BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape [0.03%]
B细胞成熟抗原在多发性骨髓瘤中的生物学作用及靶向治疗：从配体信号传导到抗原逃逸
Ebru Sezer,Seungyoun Lee,Junho Chung
Ebru Sezer
B-cell maturation antigen (BCMA; TNFRSF17) has rapidly evolved from a plasma cell survival receptor within the BAFF/APRIL network to a central therapeutic hub in multiple myeloma (MM). In this review, we first outline the gene organization,...
Dong Hyun Kim,Tae Min Kim
Dong Hyun Kim
T-cell engaging bispecific antibodies (BsAbs) have transformed the treatment paradigms for B-cell non-Hodgkin lymphomas. This review focused on 4 CD20 × CD3 BsAbs, as well as surovatamig, a CD19 × CD3 BsAb currently under investigation th...
Hyeri Ryou,Sang-Eun Jung,Hyungseok Seo
Hyeri Ryou
Glioblastoma (GBM) remains one of the most lethal primary brain tumors, with current standard therapies conferring only limited survival benefit. Although immunotherapeutic approaches have expanded treatment options, they have yet to demons...
The emergence of a new paradigm with signal 1 and signal 2 T-cell engagers in hematology [0.03%]
基于信号1和信号2的T细胞 engaging药物在血液肿瘤中的新范式临床研究
Hayoung Kwon,Chang-Han Lee
Hayoung Kwon
First-generation T-cell engagers have demonstrated significant efficacy in treating hematological malignancies by providing a potent T-cell receptor Signal 1. However, their efficacy is limited by the absence of a TCR co-stimulatory Signal ...
Chemical evolution of antibody-drug conjugates focused on linker design and conjugation strategies in hematology [0.03%]
基于连接子设计和偶联策略的抗体药物偶联物在血液系统中的化学进化
Seungbin Park,Geetanjali B Gone,Dohee Ahn et al.
Seungbin Park et al.
Antibody-drug conjugates (ADCs) have transformed the treatment of hematologic malignancies by coupling antibody selectivity with potent cytotoxic payloads. Their clinical performance depends largely on chemical design, particularly linker s...
Trispecific T cell engagers in hematological malignancies: Advancing beyond bispecific antibodies [0.03%]
三特异性T细胞衔接子在血液系统恶性肿瘤中的应用：双特异性抗体的下一个目标？
Kyung-Nam Koh,Dae Hee Kim,Hyori Kim
Kyung-Nam Koh
The success of bispecific T cell engagers (BiTEs) in hematological malignancies has catalyzed the development of trispecific antibodies that simultaneously target 3 molecular entities. These next-generation immunotherapeutics address the ke...